Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS

Jan 01 2010

• By Pharmaceutical Approvals Monthly

Related Content

Telavancin’s “Complete Response” Letter Calls For Pregnancy-Focused REMS

Mar 02 2009

Theravance Gets To Market With Vibativ, But HAP Indication Could Be Pushed To 2010

Sep 14 2009

No Shocker Here: Theravance Gets FDA "Complete Response" For Telavancin

Dec 01 2009

Antimicrobial Drug Reviews Would Need To Consider “Resistance” Under Bill

Oct 15 2007

Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin

Jan 01 2010

Telavancin Back On Road To Approval, Rescued By Sponsor’s Risk Plan

Dec 01 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window